IGM Biosciences Entered into a Clinical Collaboration Agreement with ADC to Evaluate Imvotamab (IGM-2323) + Zynlonta (loncastuximab tesirine-lpyl) for B Cell Non-Hodgkin’s Lymphoma
Shots:
- The companies collaborated to evaluate the combination of IGM’s imvotamab (IgM CD20 x CD3 T cell engaging bispecific Ab) + ADC Therapeutics’ Zynlonta (CD19-directed ADC) in the P-I study for the treatment of patients with r/r B cell NHL. The trial is expected to be initiated in Q1’23
- IGM will be responsible to conduct clinical testing for imvotamab + Zynlonta to treat r/r NHL while ADC Therapeutics will be responsible to provide the clinical expertise on Zynlonta along with drug supply to support the trial
- The results from the prior studies showed a 50% CR rate at the likely optimal 100mg dose, CRS was observed in <20% of patients treated in the titration dosing cohorts
Ref: Businesswire | Image: ADC
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
